×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Clinical Topics

Although healthcare professionals’ self‐reported evidence-based practice (EBP) knowledge, skills, attitudes, and beliefs are at a moderate to high level, this doesn’t translate into EBP implementation, according to a study in Worldviews On Evidence-Based Nursing.

Read more at Sigma . . .

On May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than 17 years of age. On the same date, the agency approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused . . .

According to a systematic review in PLOSOne, healthcare professionals generally support the use of medicinal cannabis, but they lack knowledge and are concerned about patient harm and indirect societal harms.

Read more at PLOSOne . . .

On April 19, the FDA permitted marking of the first medical device to treat attention deficit hyperactivity disorder (ADHD): Monarch external Trigeminal Nerve Stimulation (eTNS) System.

Read more at fda.gov . . .

It’s not just the United States that’s experiencing a resurgence of measles. Experts writing in the New England Journal of Medicine note that the decline in measles vaccination is causing a preventable global resurgence of the disease.

Read more at National Institute of Allergy and Infectious Diseases . . .

On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following previous platinum-containing chemotherapy.

Read more at fda.gov . . .

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing